This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Takeda Pharmaceutical Company Ltd
Drug Names(s): Topical anti-HPV Gel, 851B, TAK-851, epetirimod esylate
Description: 851B gel is a topical gel containing a peptide derived from the human papillomavirus (HPV). Application of 851B gel may stimulate the host immune system to trigger a cytotoxic T-lymphocyte response to cells that express HPV.
Deal Structure: In March 2005, 3M and Takeda entered into an exclusive co-development and joint marketing agreement to collaborate on a topical treatment for cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia. Under the terms of this agreement, 3M and Takeda will share further costs of development. Upon successful clinical development and regulatory approvals, the companies will jointly commercialize in the United States and European Union. Takeda will retain exclusive rights in Japan and certain Asian countries, and 3M will have exclusive commercialization rights in all other areas of the world.
In December 2006, Graceway Pharmaceuticals acquired 3M's pharmaceuticals operations in the United States, Canada, and Latin America. Under the agreement, Graceway Pharmaceuticals will acquire exclusive regional marketing and intellectual property rights to 3M's branded pharmaceuticals.
In March 2007, Takeda Pharmaceutical announced that it acquired the development and...See full deal structure in Biomedtracker
Partners: Valeant Pharmaceuticals International, Inc.
Additional information available to subscribers only: